Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CDK1 | P06493 | 2/20 | 0.32 |
| ▸ | CCNB1 | P14635 | 2/20 | 0.32 |
| ▸ | MGMT | P16455 | 2/20 | 0.32 |
| ▸ | CCNA2 | P20248 | 2/20 | 0.32 |
| ▸ | CDK2 | P24941 | 2/20 | 0.32 |
| ▸ | CCNA1 | P78396 | 2/20 | 0.32 |
| ▸ | NPC1 | O15118 | 1/20 | 0.31 |
| ▸ | RAB9A | P51151 | 1/20 | 0.31 |
| ▸ | LMNA | P02545 | 1/20 | 0.31 |
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23037265 | 0.71 | CDK1 (0.47) | CDK1CCNB1MGMTCCNA2CDK2 | |
| SCHEMBL23113063 | 0.70 | CDK1 (0.35) | CDK1CCNB1MGMTCCNA2CDK2 | |
| SCHEMBL1131137 | 0.69 | HSP90AA1 (0.44) | NPC1RAB9ALMNAHSP90AA1 | |
| SCHEMBL24728017 | 0.67 | MAPT (0.41) | CDK1CCNB1MGMTCCNA2CDK2 | |
| SCHEMBL10865363 | 0.66 | HSP90AA1 (0.41) | CDK1CCNB1CCNA2CDK2CCNA1 | |
| SCHEMBL9599405 | 0.65 | TSHR (0.39) | NPC1RAB9ALMNAHSP90AA1 | |
| SCHEMBL24727871 | 0.65 | LMNA (0.38) | LMNAHSP90AA1 | |
| SCHEMBL3132522 | 0.65 | HSP90AB1 (0.41) | NPC1RAB9ALMNAHSP90AA1 | |
| SCHEMBL441545 | 0.62 | HSP90AB1 (0.43) | CCNA2CDK2CCNA1NPC1RAB9A | |
| SCHEMBL30562916 | 0.62 | HSP90AB1 (0.43) | CCNA2CDK2CCNA1NPC1RAB9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20210079031-A1 | NEW ANTIVIRAL ACYCLONUCLEOSIDE ANALOGUES | NEOVIRTECH (FR) | 2021-03-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210079031-A1 | NEW ANTIVIRAL ACYCLONUCLEOSIDE ANALOGUES | TYMP, EIF2AK2, PNP | CDK1 256/4885CCNB1 485/4885MGMT 1660/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.